Pfizer’s presence at ASCO 2024
Positive results from ECHELON-3 Phase 3 study
Regimen produced clinically meaningful improvement in overall survival for certain patients with relapsed/refractory diffuse large b-cell lymphoma (DLBCL).
Find Out MoreNew 4-year data in advanced classical Hodgkin lymphoma
Takeda and Pfizer announce positive four-year results from Phase 3 HD21 trial of combination treatment regimen in frontline classical Hodgkin lymphoma.
Find Out MoreNew data from CROWN study
Five year follow-up data shows prolonged progression-free survival in ALK-positive advanced lung cancer.
Find Out MoreUnderstanding ALK-Positive Advanced Non-Small Cell Lung Cancer
Background information about a rare, aggressive form of lung cancer called ALK-positive non-small cell lung cancer.
Find Out MoreBreaking new ground with lung cancer research
Advances in scientific research have brought new hope for patients with a rare, aggressive form of lung cancer.
Find Out MoreHighlighting progress in accelerating breakthrough cancer medicines at ASCO
Pfizer is showcasing new research across the company’s key tumor areas and core scientific modalities, including small molecules, antibody-drug conjugates and bispecific antibodies.
Find Out MorePfizer-sponsored abstracts at ASCO
More than 50 abstracts will be presented from Pfizer’s broadened portfolio of approved and pipeline therapies.
See Our Abstract ListPfizer Abstract Plain Language Summaries (APLS)
To help non-scientists better understand the latest research, we are providing abstract plain language summaries for key data at ASCO.
Find Out MoreDriving cutting-edge science forward
Pfizer leaders share progress toward our vision: a world where people with cancer live better and longer lives.
Find Out MorePress Releases
All Pfizer published press releases by date and/or category of news
12.20.2021 Medicines Research Pfizer’s VYNDAQEL®/VYNDAMAX® Reduced the Risk of All-Cause Mortality by 41% Among Patients with Transthyretin Amyloid Cardiomyopathy, Five-Year Follow-Up Data Demonstrate 12.15.2021 Research Pfizer Invests $68.5 Million in New State-of-the-Art Facility in Durham, North Carolina to Further Advance Gene Therapy Capabilities 12.14.2021 Covid-19 Medicines Research Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death 12.12.2021 Research Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy 12.10.2021 Research Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer 12.02.2021 Research AWS Helps Pfizer Accelerate Drug Development And Clinical Manufacturing 11.24.2021 Research Vaccines Pfizer Announces Topline Results from Phase 2b Trial of Vupanorsen in Statin-treated Participants with Dyslipidemia 11.22.2021 Covid-19 Research Vaccines Follow-Up Data From Phase 3 Trial of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age 11.19.2021 Research Arvinas And Pfizer Announce Updated Phase 1 Dose Escalation Data For ARV-471 To Be Presented In Spotlight Poster Session At 2021 San Antonio Breast Cancer Symposium 11.05.2021 Research Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study 10.21.2021 Research Vaccines Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine 10.19.2021 Research Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress
Trust in Technology – A Snapshot
Pfizer surveyed adults in 10 countries across the Global North and South to better understand the general population's trust in incorporating technology into the management of their healthcare. The results showed that 6 in 10 trust technology in this setting but that means 4 in 10 are at risk of being left behind. Our findings underscored that patients won’t feel the full benefits of that technology if we don’t have trusted people – specifically health care providers – delivering it. We must partner with patients, healthcare providers, policy makers and others in the life sciences and tech industries to build trust in the technologies that are fueling the future of health.
Downloadable InfographicDetails
Media Asset Library
A collection of assets for use by media.
Partnering News
The latest news from Pfizer and its strategic partners
12.05.2023 Corporate Partnerships Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program 12.04.2023 Corporate Partnerships Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15
Media Contacts
Pfizer Media Relations
We encourage everyone to view our press releases, press statements, and press kits to stay up to date on Pfizer news.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.
Media Contacts
General email
[email protected]
United States, Canada and Latin America
+1 212.733.1226
Europe, the Middle East and Africa
+44-(0)173.733.2335
[email protected]
Asia Pacific
+65.918.732.47
What we need
To best help us help you, please be prepared to provide your name and email address, a summary of the article you're working on and your deadline.
Other Frequently Visited Links
For more, see these helpful and often used sections of Pfizer.com
Pfizer Wire
Stay up to date on the latest news and alerts through the Pfizer Wire
Sign up to receive real-time updates on Pfizer’s news from the Pfizer Media Relations team delivered directly to your inbox.
Sign Up NowDetails